Identification
- Summary
Chymotrypsin is a digestive enzyme supplement used as supportive therapy to manage the side effects associated with conventional chemotherapy, radiotherapy, and hormone therapy.
- Generic Name
- Chymotrypsin
- DrugBank Accession Number
- DB09375
- Background
Chymotrypsin (EC 3.4.21.1) is a digestive enzyme that promotes proteolysis, or the breakdown of proteins and polypeptides. It is a serine protease synthesized in the pancreas and is a vital component in the pancreatic juice. Like most proteolytic enzymes, chymotrypsin is activated from its inactive zymogen precursor, chymotrypsinogen, in presence of Trypsin. Chymotrypsin is the most abundant pancreatic proteases that represent up to 10-20% of the total protein synthesized by the exocrine pancreas 1. Chymotrypsin contains both the catalytic triad and oxyanion hole, and the tertiary structure of chymotrypsin is similar to Trypsin 3.
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Synonyms
- alpha-Chymotrypsin
- Chymotrypsin
- Chymotrypsin A
- Chymotrypsin B
- Chymotrypsine
- Chymotrypsinum
- Quimotripsina
Pharmacology
- Indication
No therapeutic indications.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Chymotrypsin is a digestive enzyme synthesized in the pancreas that plays an essential role in proteolysis, or the breakdown of proteins and polypeptides. As a component in the pancreatic juice, chymotrypsin aids in the digestion of proteins in the duodenum by preferentially cleaving peptide amide bonds.
- Mechanism of action
Chymotrypsin is synthesized by pancreatic acinar cells as an inactive precursor, chymotrypsinogen, that is secreted to the duodenum and activated via trypsin-induced cleavage. It also induces its own activation by cleaving essential amino acid residues in the oxyanion hole to produce α-Chymotrypsin, which is a more stable form than π-Chymotrypsin. Residues His-57, Asp-102, and Ser-195 form the catalytic triad while residues 189–195, 214–220, and 225–228 form the primary substrate-binding pocket called S1 binding pocket 3. Residue 189 in the polar serine residue that lies at the bottom of the S1 binding pocket 3. Chymotrypsin favors aromatic residues like phenylalanine, tyrosine, and tryptophan 3 but may hydrolyze other bonds in peptides at slower rates.
- Absorption
No pharmacokinetic data available.
- Volume of distribution
No pharmacokinetic data available.
- Protein binding
No pharmacokinetic data available.
- Metabolism
No pharmacokinetic data available.
- Route of elimination
No pharmacokinetic data available.
- Half-life
No pharmacokinetic data available.
- Clearance
No pharmacokinetic data available.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
No toxicokinetic data available.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetylcysteine The therapeutic efficacy of Acetylcysteine can be decreased when used in combination with Chymotrypsin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Catarase Pws 300units/2ml Powder, for solution 300 unit / 2 mL Ophthalmic Iolab Pharmaceuticals 1988-12-31 1997-07-23 Canada 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Wobe - Mugos magensaftresistente Tabletten Chymotrypsin (12000 FIP units) + Papain (270 FIP units) + Trypsin (1740 FIP units) Tablet, delayed release Oral Mucos Pharma Gmb H & Co.Kg 1976-02-13 Not applicable Austria 
Wobenzym magensaftresistente Tabletten Chymotrypsin (300 FIP units) + Bromelains (225 FIP units) + Pancrelipase (300 protease units) + Papain (164 FIP units) + Rutoside trihydrate (50 mg) + Trypsin (720 FIP units) Tablet, delayed release Oral Mucos Pharma Gmb H & Co.Kg 1984-03-30 Not applicable Austria
Categories
- ATC Codes
- S01KX01 — ChymotrypsinB06AA04 — Chymotrypsin
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- BVS505O332
- CAS number
- 9004-07-3
References
- General References
- Reseland JE, Larsen F, Solheim J, Eriksen JA, Hanssen LE, Prydz H: A novel human chymotrypsin-like digestive enzyme. J Biol Chem. 1997 Mar 21;272(12):8099-104. [Article]
- Di Cera E: Serine proteases. IUBMB Life. 2009 May;61(5):510-5. doi: 10.1002/iub.186. [Article]
- Ma W, Tang C, Lai L: Specificity of trypsin and chymotrypsin: loop-motion-controlled dynamic correlation as a determinant. Biophys J. 2005 Aug;89(2):1183-93. doi: 10.1529/biophysj.104.057158. Epub 2005 May 27. [Article]
- External Links
- KEGG Drug
- D03484
- PubChem Substance
- 347910449
- 2530
- ChEMBL
- CHEMBL1201465
- Wikipedia
- Chymotrypsin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder, for solution Ophthalmic 300 unit / 2 mL Tablet, delayed release Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at November 30, 2015 19:10 / Updated at May 14, 2021 01:05